Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-A "knock-out" is yet to be delivered-Authors' reply

Affiliations

Editorial

W Ray Kim et al. Aliment Pharmacol Ther. 2022 May.

. 2022 May;55(10):1344-1345.

doi: 10.1111/apt.16920.

No abstract available

Comment on

Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH. Hsu YC, et al. Am J Gastroenterol. 2020 Feb;115(2):271-280. doi: 10.14309/ajg.0000000000000428. Am J Gastroenterol. 2020. PMID: 31634265
Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-a "knock-out" is yet to be delivered.
Tonthat AV, Zhou K. Tonthat AV, et al. Aliment Pharmacol Ther. 2022 May;55(10):1342-1343. doi: 10.1111/apt.16822. Aliment Pharmacol Ther. 2022. PMID: 35472182 No abstract available.

1. Tonthat AV, Zhou K. Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir - a “knock-out” is yet to be delivered. Aliment Pharmacol Ther. 2022;55:1342-1343.
1. Kim WR, Telep LE, Jump B, et al. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Aliment Pharmacol Ther. 2022;55:628-635.
1. Suissa S. The number needed to treat: 25 years of trials and tribulations in clinical research. Rambam Maimonides Med J. 2015;6(3):e0033.
1. Austin PC, Laupacis A. A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: a review. Int J Biostat. 2011;7(1):6.
1. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800-6.